BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib in Oncology
Shots:
- BridgeBio to receive ~$2.45B+ including ~$100M in up front- regulatory and commercial milestones along with royalties on net sales of Infigratinib from Helsinn Group. The agreement is expected to close in Q2’21
- Helsinn to co-commercialize infigratinib in oncology and other indications except for skeletal dysplasia indications in the US and will equally share profits and losses. Additionally- BridgeBio will retain all rights in skeletal dysplasia including achondroplasia
- Helsinn will lead and have exclusive commercialization rights for infigratinib in non-skeletal dysplasia indications outside the US excluding China- Hong Kong- and Macau. Additionally- the FDA is reviewing an NDA for infigratinib to treat patients with previously treated- FGFR-mutant cholangiocarcinoma
Ref: BridgeBio | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com